NIVESTYM Solution for injection Ref.[10897] Active ingredients: Filgrastim

Source: FDA, National Drug Code (US)  Revision Year: 2019 

Product description

Filgrastim-aafi is a 175 amino acid human granulocyte colony-stimulating factor (G-CSF) manufactured by recombinant DNA technology.

NIVESTYM is produced by Escherichia coli (E coli) bacteria into which has been inserted the human granulocyte colony-stimulating factor gene. NIVESTYM has a molecular weight of 18‚799 daltons. The protein has an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis‚ except for the addition of an N-terminal methionine necessary for expression in E coli. Because NIVESTYM is produced in E coli‚ the product is non-glycosylated and thus differs from G-CSF isolated from a human cell.

NIVESTYM is a sterile‚ clear‚ colorless‚ preservative-free liquid containing filgrastim-aafi injection for subcutaneous or intravenous use. The product is available in single-dose vials and prefilled syringes. The single-dose vials contain either 300 mcg/mL or 480 mcg/1.6 mL of filgrastim-aafi. The single-dose prefilled syringes contain either 300 mcg/0.5 mL or 480 mcg/0.8 mL of filgrastim-aafi. See Table 4 below for product composition of each single-dose vial or prefilled syringe.

Table 4. Product Composition:

 300mcg/mL Vial 480 mcg/1.6 mL Vial 300 mcg/0.5 mL Syringe 480 mcg/0.8 mL Syringe
Filgrastim-aafi 300 mcg 480 mcg 300 mcg 480 mcg
Acetate 0.59 mg 0.94 mg 0.295 mg 0.472 mg
Polysorbate 80 0.04 mg 0.064 mg 0.02 mg 0.032 mg
Sodium 0.035 mg 0.056 mg 0.0175 mg 0.028 mg
Sorbitol 50 mg 80 mg 25 mg 40 mg
Water for Injection USP
q.s. ad* 		1 mL 1.6 mL 0.5 mL 0.8 mL

* quantity sufficient to make

Dosage Forms and Strengths

Vial:

  • Injection: 300 mcg/mL of a clear, colorless solution in a single-dose vial
  • Injection: 480 mcg/1.6 mL of a clear, colorless solution in a single-dose vial

Prefilled Syringe:

  • Injection: 300 mcg/0.5 mL of a clear, colorless solution in a single-dose prefilled syringe with BD UltraSafe Plus Passive Needle Guard
  • Injection: 480 mcg/0.8 mL of a clear, colorless solution in a single-dose prefilled syringe with BD UltraSafe Plus Passive Needle Guard
How Supplied

Vials:

Injection: Single-dose vials containing 300 mcg/mL of a sterile, clear, colorless, preservative-free filgrastim-aafi solution. Dispensing packs of 10 vials (NDC 0069-0293-10).

Injection: Single-dose vials containing 480 mcg/1.6 mL (300 mcg/mL) of a sterile, clear, colorless, preservative-free filgrastim-aafi solution. Dispensing packs of 10 vials (NDC 0069-0294-10).

Prefilled Syringes:

Injection: Single-dose prefilled syringe with BD UltraSafe Plus Passive Needle Guard, containing 300 mcg/0.5 mL of a sterile, clear, colorless, preservative-free filgrastim-aafi solution.

  • Pack of 1 prefilled syringe (NDC 0069-0291-01).
  • Pack of 10 prefilled syringes (NDC 0069-0291-10).

Injection: Single-dose, prefilled syringe with BD UltraSafe Plus Passive Needle Guard, containing 480 mcg/0.8 mL of a sterile, clear, colorless, preservative-free filgrastim-aafi solution.

  • Pack of 1 prefilled syringe (NDC 0069-0292-01).
  • Pack of 10 prefilled syringes (NDC 0069-0292-10).

The NIVESTYM syringe plunger stopper and needle cover are not made with natural rubber latex [see Dosage and Administration (2.5)].

Manufactured by: Hospira, Inc., a Pfizer Company, Lake Forest, IL 60045 USA, US License No. 1974

Drugs

Drug Countries
NIVESTYM Canada, United States
 
Next: Usage >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈